dovramilast
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2025 (NCT07172659)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Phosphodiesterase 4INHIBITOR
Phosphodiesterase 4 inhibitor
- Phosphodiesterase isozyme 4INHIBITOR
PDE4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOc1cc([C@@H](CS(C)(=O)=O)N2Cc3cccc(NC(=O)C4CC4)c3C2=O)ccc1OC- Mol. weight
- 472.56 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297460 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07172659 | Phase 2 | Oct 31, 2025 | Medicines Development for Global Health |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Medicines Development for Global Health | For profit | 1 | 1 | 1 | 2025 |
1 organizations
Page 1 / 1